Research programme: metabolic disorders therapeutics - DiscoveryBioMed

Drug Profile

Research programme: metabolic disorders therapeutics - DiscoveryBioMed

Latest Information Update: 10 Apr 2015

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator DiscoveryBioMed
  • Class
  • Mechanism of Action Adiponectin stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Research Diabetes mellitus; Obesity

Most Recent Events

  • 08 Apr 2015 DicoveryBioMed receives phase II SBIR grant from National Institutes of Health and its National Institute of Diabetes, Digestive and Kidney Diseases (NIDDK) for development of drugs for diabetes and obesity
  • 07 Oct 2014 Active research is ongoing for metabolic disease drug discovery programme
  • 02 Jul 2012 DiscoveryBioMed receives phase I SBIR grant from National Center for Complementary and Alternative Medicine for Metabolic disorder drug development
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top